In the long grass at the SIU by Cooper, Alan
Iremember a senior academic telling a story of howhe was witness to the first airing of some seminalstudy; something of the order of importance of the
first monoclonal antibody (it might even have been
that)... at a late session on the last working day of a
conference with only the speaker, the chairman and a
couple of others present. 
Anyone who wants to know what The Great and
Good had to say about trendy issues at the recent
Société Internationale d'Urologie (SIU) meeting in
Shanghai can undoubtedly find a number of reports
documenting these things. What this article sets out to
do is look through the (actually or potentially) cancer-
related offerings in the un-moderated poster sessions
of that meeting to see what promising material was on
offer but had not made a big splash with the selection
committee. Some will perhaps never figure in our
working lives, many will lurk indefinitely in our
peripheral vision; one or two just might come to have
real significance for us. I know no better than anyone
which these might be.
At this point I have to declare my interests, because
they inevitably inform my selection, although I have
consciously fought against this. I am an elderly cell
biologist whose more recent interest has been imaging
drug uptake in live cells in vitro, of which more below.
But I was first attracted into urology and cancer by the
late Professor Sir James Fraser at Southampton, who
set me to work looking for potential immunological
sequelae of cryosurgery using the most hideous liquid
nitrogen probes on guinea-pigs [1]. But for the
excellent healing properties of cryolesions I would still
have the scars on my stomach from wielding these
things. So let’s start with cryosurgery, which is not
exactly in the longest of long grass, but perhaps has
not hit the flag the way we might have hoped in the
1970s. The format throughout will be to comment on
topics, giving their abstract and page number, as they
appear in the conference supplement of Urology [2]
A report (UP-2.144, pS277) from Tel Aviv gave
details of 33 patients who had received salvage
cryotherapy for radio recurrent prostate cancer.
Biochemical recurrence-free survival at two years was
43% (14 patients). Complications were seen in 21
cases. Despite the high complication rate the authors
feel the method has potential in selected cases, but
larger studies and more follow-up are required. This
type of conclusion is typical for a method that has its
attractions but performs sub-optimally. It is good that
these techniques are kept under review; advances in
technology have been substantial but perhaps more is
required if cryotherapy is to become more widely
used. It is in general terms competing with other
forms of ablative treatment, including radio-frequency
ablation, which was the subject of two posters (UP-
1063, pS189 & UP-1066, p190), both concerned with
the treatment of small renal tumours. A total of only
64 patients were treated in both series combined. One
claimed over 90% cancer control rate, complications
ran at 10-15%. Inevitably the cases selected were
those in older or less fit patients where more invasive
methods were not possible. It is a common feature
with new or developing strategies that they have to
cut their teeth in the least promising scenarios.
However another way of introducing new technology
is to use it on benign conditions first where failure is
a little more acceptable. Such seems to be the
approach towards introducing vaporisation techniques
with two descriptions of its use in treating benign
prostatic hyperplasia (UP-1.044, pS184 & UP-3.085,
pS320). Both reported encouraging results in terms of
both safety and efficacy. It remains to be seen who
may take the plunge by using vaporisation for a
malignant condition and, if so, when.
From hi-tech ablation to conventional surgery, it
was particularly pleasing for me to read that as my
progress towards octogenarian status accelerates, I
need not then fear too much the prospect of radical
cystectomy which, at least in the Rajiv Gandhi
Institute, has “acceptable morbidity and mortality”
and potentially offers sustained disease-free survival
in that age group (UP-3.031, pS303). More on
intermediate technology later.
Having considered the ablation or removal of
cancerous lesions, it is appropriate to move on to tissue
engineering for reconstruction [3], another topic which
requires technological innovation to shoot it from the
short rough. UP-1.054, pS187 describes how linguinal
mucosa cells can be successfully cultured and seeded
onto bladder acellular matrix graft (BAMG) material in
vitro. A further development of the BAMG concept
described in UP-2.179, pS288 was to construct a tissue
sandwich with urothelial cells on one side of the
matrix and smooth muscle cells on the other,
mimicking the native bladder structure and providing,
the authors claim, a “good technology for further
clinical bladder regeneration by the tissue engineering
approach”. Among the posters relating to products
adjunctive to surgery was a description of the
successful experimental use of a new surgical glue
(UP-1.051, pS186). The abstract concentrates on the
properties of the glue; apart from being developed from
food additives, nothing is said about its composition.
Moving from surgery to chemotherapy there were
three kinase-related studies that caught my eye. One
was to do with resistance, or perhaps more accurately,
protection of a urothelial cancer cell line to mitomycin,
mediated by fibronectin through the P13-k/Akt
signaling pathway (UP-3.009, pS297). This is the
subject of a full publication now in print [4]. The next-
door poster (UP-3.010, pS297) concerned
phosphoglycerate kinase as a potential therapeutic
target affecting angiogenesis, but from
immunohistochemical analysis of clinical bladder
cancer material. The third study was on invasiveness
in renal cancer cells promoted by gamma-
aminobutyric acid through its receptor activation and a
MAPKinase pathway. Attempts to individualise
chemotherapy are always with us [5] but seem to await
the breakthroughs that will see them widely adopted.
Poster UP-3.001 offered an autologous cell culture with
cyto-immunoassay protocol for tailoring drug
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combinations and doses in transitional cell
carcinoma of the bladder. It fared well, albeit
against a control group receiving BCG only. 
It would be nice at this time of year to report
an additional, less seasonal and more socially
responsible use for mistletoe. Unfortunately, its
prospects as the source of a therapeutic agent
in bladder cancer do not look bright (UP-3.040,
pS306), although in this early study the
preparation was probably not tested to its
maximum tolerated dose as no adverse effects
or biochemistry were observed. 
There is an abstract in the book (UP-1.136,
pS213) on lycopene chemoprevention in
prostate cancer which unfortunately did not
make it to the conference as a poster. That was
a disappointment for me personally, as I too
have worked with lycopene for its affinity with
prostasomes and consequent potential effects
on fertility as well as cancer [6,7]. Raising
serum lycopene levels by administering the
agent in capsular form to prostate cancer
patients being screened for recurrent disease
was accompanied by decreased PSA
measurement, compared with rising levels in a
placebo control group. Although deliberately
avoiding the major presentations, I have to
remark here that in a plenary lecture on the
nutritional management of prostate cancer,
among the supplements and micronutrients
currently being tested, lycopene was
considered the only one holding up well at the
moment. Concerning the aetiology of prostate
cancer, one poster noted that the presence of
prostate calculi, while not constituting a risk
factor, was more common in patients with
prostate cancer and associated with a higher
Gleason score. (UP-1.114, pS205). Another
presentation (UP-2.038, pS244) suggests that
BK Polyomavirus can be horizontally as well
as vertically transmitted within communities.
BKV has a possible role in the initiation of
prostate cancer by encoding oncoproteins
interfering with tumour suppressor gene
pathways. [8] 
Mathematical modeling is a contentious
issue [9] that will persist at the fringes of
oncological research until computational
power and logic progress sufficiently to make
meaningful outcomes possible. A small step
in this direction is suggested (UP-1.100,
pS201) with a program that refines data from
PSA measurements to give a “high diagnostic
accuracy” (positive and negative predictive
values ~85%). Less technically ambitious
and with a result suggesting that progress is
not always in a forward direction for every
circumstance, the application of Partin tables
to an Asian population revealed not just that
they were a useful tool, but that the 1997
tables performed better than the more recent
2001 version [10,11]! 
Another example of beneficially retrograde
progress is the description of a simplified
TURP procedure “especially for the third
world” (UP-3.074, pS317). The unrelenting
march of technological sophistication (note
the etymology of sophisticated is as a term of
disapprobation) should not completely
overshadow the need for intermediate
technology systems for less affluent medical
institutions (and patients) [12].
The application of sociological thinking to
medicine produces diverse results and strange
language. On the one hand there was a very
practical study of prostate cancer awareness
in male Chinese city-dwellers (UP-1.134)
although the result that more education is
desirable was somewhat predicatable. Even
more startling was a “Socio-Health Study”
(poster number UP-2.137) on attitudes of
prostate cancer patients towards their disease.
The abstract starts “Considering the ever
more prominent role of the patient within
healthcare systems …” That is either a huge
and hopefully unfair indictment of relatively
recent medical practice or a statement of the
extremely obvious. The observation that a
vast majority of patients want to maintain
their lifestyles and social or family contacts is
unsurprising and it is to be hoped that it
would have long been a factor in treatment
scheduling.
There was also an interesting historical
perspective on the origins of haematoxylin
and its importance in the development of
histopathology in general and Gleason
scoring in particular (UP-3.094, pS323).
I have to finish as I started, with a personal
note. I too was there in the deep rough at the
SIU with a description of how my passion of
recent years, cellular imaging of drug uptake
using unlabelled agents visualised in live cells,
finds its latest expression in the investigation
of whether mid-range Fourier Transform
Infrared (FT-IR) microspectroscopy offers any
solutions (UP-1.119 pS207). In this poster I
concentrated on the use of oil overlays to
protect live cells during the imaging process.
I’m not at all sure that FT-IR will ever rival
fluorescence as an application in live-cell
imaging, but in science as in romance, great
fun can be had in the long grass - sometimes
with unexpectedly creative results. n
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Figure 1: At many meetings (especially surgical ones) form seems to trump substance. Not necessarily so in the SIU
Long Grass!
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